{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:26:31Z","timestamp":1780673191262,"version":"3.54.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003356","name":"Gazi \u00dcniversitesi","doi-asserted-by":"publisher","award":["01\/2019-34."],"award-info":[{"award-number":["01\/2019-34."]}],"id":[{"id":"10.13039\/501100003356","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s10067-022-06070-w","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T22:02:28Z","timestamp":1642716148000},"page":"1381-1389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The impact of anti-TNF treatment on Wnt signaling, noggin, and cytokine levels in axial spondyloarthritis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5880-4974","authenticated-orcid":false,"given":"Nuh","family":"Atas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ba\u011fdag\u00fcl","family":"\u00c7ak\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Bak\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"U\u00e7ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Sat\u0131\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem Tu\u011f\u00e7e","family":"G\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra Durmu\u015f","family":"Demirel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakan","family":"Babao\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhan Bilici","family":"Salman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asl\u0131han Avano\u011flu","family":"G\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hazan","family":"Karadeniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeminur","family":"Haznedaro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna","family":"G\u00f6ker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Akif","family":"\u00d6zt\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Tufan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"issue":"10089","key":"6070_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","volume":"390","author":"J Sieper","year":"2017","unstructured":"Sieper J, Poddubnyy D (2017) Axial spondyloarthritis. Lancet 390(10089):73\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(16)31591-4","journal-title":"Lancet"},{"issue":"3","key":"6070_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.berh.2010.01.005","volume":"24","author":"G Schett","year":"2010","unstructured":"Schett G, Rudwaleit M (2010) Can we stop progression of ankylosing spondylitis? Best Pract Res Clin Rheumatol 24(3):363\u2013371. https:\/\/doi.org\/10.1016\/j.berh.2010.01.005","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"6","key":"6070_CR3","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210770","journal-title":"Ann Rheum Dis"},{"issue":"9313","key":"6070_CR4","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/s0140-6736(02)08215-6","volume":"359","author":"J Braun","year":"2002","unstructured":"Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187\u20131193. https:\/\/doi.org\/10.1016\/s0140-6736(02)08215-6","journal-title":"Lancet"},{"issue":"7","key":"6070_CR5","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1002\/art.21913","volume":"54","author":"D van der Heijde","year":"2006","unstructured":"van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136\u20132146. https:\/\/doi.org\/10.1002\/art.21913","journal-title":"Arthritis Rheum"},{"issue":"2","key":"6070_CR6","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS et al (2016) American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol 68(2):282\u2013298. https:\/\/doi.org\/10.1002\/art.39298","journal-title":"Arthritis Rheumatol"},{"issue":"suppl_6","key":"6070_CR7","doi-asserted-by":"publisher","first-page":"vi4","DOI":"10.1093\/rheumatology\/key001","volume":"57","author":"D Simone","year":"2018","unstructured":"Simone D, Al Mossawi MH, Bowness P (2018) Progress in our understanding of the pathogenesis of ankylosing spondylitis. Rheumatology (Oxford) 57(suppl_6):vi4\u2013vi9. https:\/\/doi.org\/10.1093\/rheumatology\/key001","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"6070_CR8","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao CC, Sathe M, Grein J et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18(7):1069\u20131076. https:\/\/doi.org\/10.1038\/nm.2817","journal-title":"Nat Med"},{"issue":"3","key":"6070_CR9","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/ni.1698","volume":"10","author":"MJ McGeachy","year":"2009","unstructured":"McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM et al (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10(3):314\u2013324. https:\/\/doi.org\/10.1038\/ni.1698","journal-title":"Nat Immunol"},{"issue":"1","key":"6070_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/s13075-016-1200-1","volume":"18","author":"RD Inman","year":"2016","unstructured":"Inman RD, Baraliakos X, Hermann KA, Braun J, Deodhar A, van der Heijde D et al (2016) Serum biomarkers and changes in clinical\/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. Arthritis Res Ther 18(1):304. https:\/\/doi.org\/10.1186\/s13075-016-1200-1","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"6070_CR11","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3109\/03009742.2012.735700","volume":"42","author":"GX Li","year":"2013","unstructured":"Li GX, Wang S, Duan ZH, Zeng Z, Pan FM (2013) Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis. Scand J Rheumatol 42(3):226\u2013231. https:\/\/doi.org\/10.3109\/03009742.2012.735700","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"6070_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1136\/annrheumdis-2011-200216","volume":"71","author":"GR Heiland","year":"2012","unstructured":"Heiland GR, Appel H, Poddubnyy D, Zwerina J, Hueber A, Haibel H et al (2012) High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 71(4):572\u2013574. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200216","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6070_CR13","doi-asserted-by":"publisher","first-page":"R216","DOI":"10.1186\/ar4055","volume":"14","author":"CG Saad","year":"2012","unstructured":"Saad CG, Ribeiro AC, Moraes JC, Takayama L, Goncalves CR, Rodrigues MB et al (2012) Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy? Arthritis Res Ther 14(5):R216. https:\/\/doi.org\/10.1186\/ar4055","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"6070_CR14","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1007\/s00296-011-1981-0","volume":"32","author":"SR Kwon","year":"2012","unstructured":"Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY et al (2012) Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 32(8):2523\u20132527. https:\/\/doi.org\/10.1007\/s00296-011-1981-0","journal-title":"Rheumatol Int"},{"issue":"3","key":"6070_CR15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/ng0396-315","volume":"12","author":"JT Thomas","year":"1996","unstructured":"Thomas JT, Lin K, Nandedkar M, Camargo M, Cervenka J, Luyten FP (1996) A human chondrodysplasia due to a mutation in a TGF-beta superfamily member. Nat Genet 12(3):315\u2013317. https:\/\/doi.org\/10.1038\/ng0396-315","journal-title":"Nat Genet"},{"issue":"1","key":"6070_CR16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ng0997-18","volume":"17","author":"A Polinkovsky","year":"1997","unstructured":"Polinkovsky A, Robin NH, Thomas JT, Irons M, Lynn A, Goodman FR et al (1997) Mutations in CDMP1 cause autosomal dominant brachydactyly type C. Nat Genet 17(1):18\u201319. https:\/\/doi.org\/10.1038\/ng0997-18","journal-title":"Nat Genet"},{"key":"6070_CR17","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev.cellbio.16.1.191","volume":"16","author":"BR Olsen","year":"2000","unstructured":"Olsen BR, Reginato AM, Wang W (2000) Bone development. Annu Rev Cell Dev Biol 16:191\u2013220. https:\/\/doi.org\/10.1146\/annurev.cellbio.16.1.191","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"10","key":"6070_CR18","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/nrg1178","volume":"4","author":"KA Waite","year":"2003","unstructured":"Waite KA, Eng C (2003) From developmental disorder to heritable cancer: it\u2019s all in the BMP\/TGF-beta family. Nat Rev Genet 4(10):763\u2013773. https:\/\/doi.org\/10.1038\/nrg1178","journal-title":"Nat Rev Genet"},{"issue":"3","key":"6070_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/35043051","volume":"1","author":"J Massague","year":"2000","unstructured":"Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1(3):169\u2013178. https:\/\/doi.org\/10.1038\/35043051","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"6070_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.5966\/sctm.2015-0249","volume":"5","author":"J Fan","year":"2016","unstructured":"Fan J, Im CS, Guo M, Cui ZK, Fartash A, Kim S et al (2016) Enhanced osteogenesis of adipose-derived stem cells by regulating bone morphogenetic protein signaling antagonists and agonists. Stem Cells Transl Med 5(4):539\u2013551. https:\/\/doi.org\/10.5966\/sctm.2015-0249","journal-title":"Stem Cells Transl Med"},{"issue":"36","key":"6070_CR21","doi-asserted-by":"publisher","first-page":"26450","DOI":"10.1074\/jbc.M703282200","volume":"282","author":"DC Wan","year":"2007","unstructured":"Wan DC, Pomerantz JH, Brunet LJ, Kim JB, Chou YF, Wu BM et al (2007) Noggin suppression enhances in vitro osteogenesis and accelerates in vivo bone formation. J Biol Chem 282(36):26450\u201326459. https:\/\/doi.org\/10.1074\/jbc.M703282200","journal-title":"J Biol Chem"},{"issue":"6","key":"6070_CR22","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1172\/JCI23738","volume":"115","author":"RJ Lories","year":"2005","unstructured":"Lories RJ, Derese I, Luyten FP (2005) Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 115(6):1571\u20131579. https:\/\/doi.org\/10.1172\/JCI23738","journal-title":"J Clin Invest"},{"issue":"1","key":"6070_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1002\/art.27231","volume":"62","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M et al (2010) Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 62(1):150\u2013158. https:\/\/doi.org\/10.1002\/art.27231","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6070_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3109\/03009742.2013.805241","volume":"43","author":"M Korkosz","year":"2014","unstructured":"Korkosz M, Gasowski J, Leszczynski P, Pawlak-Bus K, Jeka S, Siedlar M et al (2014) Effect of tumour necrosis factor-alpha inhibitor on serum level of dickkopf-1 protein and bone morphogenetic protein-7 in ankylosing spondylitis patients with high disease activity. Scand J Rheumatol 43(1):43\u201348. https:\/\/doi.org\/10.3109\/03009742.2013.805241","journal-title":"Scand J Rheumatol"},{"issue":"9","key":"6070_CR25","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","volume":"33","author":"MA Machado","year":"2013","unstructured":"Machado MA, Barbosa MM, Almeida AM, de Araujo VE, Kakehasi AM, Andrade EI et al (2013) Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 33(9):2199\u20132213. https:\/\/doi.org\/10.1007\/s00296-013-2772-6","journal-title":"Rheumatol Int"},{"issue":"4","key":"6070_CR26","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/art.20977","volume":"52","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Davis J, Tsuji W, Braun J (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52(4):1216\u20131223. https:\/\/doi.org\/10.1002\/art.20977","journal-title":"Arthritis Rheum"},{"issue":"12","key":"6070_CR27","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1002\/art.23044","volume":"56","author":"RG Lambert","year":"2007","unstructured":"Lambert RG, Salonen D, Rahman P, Inman RD, Wong RL, Einstein SG et al (2007) Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 56(12):4005\u20134014. https:\/\/doi.org\/10.1002\/art.23044","journal-title":"Arthritis Rheum"},{"issue":"10","key":"6070_CR28","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landewe R, Baraliakos X, Houben H, van Tubergen A, Williamson P et al (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58(10):3063\u20133070. https:\/\/doi.org\/10.1002\/art.23901","journal-title":"Arthritis Rheum"},{"issue":"4","key":"6070_CR29","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","volume":"73","author":"X Baraliakos","year":"2014","unstructured":"Baraliakos X, Haibel H, Listing J, Sieper J, Braun J (2014) Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 73(4):710\u2013715. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202698","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6070_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1136\/ard.2011.154799","volume":"71","author":"J Braun","year":"2012","unstructured":"Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S et al (2012) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 71(5):661\u2013667. https:\/\/doi.org\/10.1136\/ard.2011.154799","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6070_CR31","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"M Rudwaleit","year":"2011","unstructured":"Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT et al (2011) The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 70(1):25\u201331. https:\/\/doi.org\/10.1136\/ard.2010.133645","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"6070_CR32","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S van der Linden","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361\u2013368. https:\/\/doi.org\/10.1002\/art.1780270401","journal-title":"Arthritis Rheum"},{"key":"6070_CR33","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s13075-016-0949-6","volume":"18","author":"FM Milanez","year":"2016","unstructured":"Milanez FM, Saad CG, Viana VT, Moraes JC, Perico GV, Sampaio-Barros PD et al (2016) IL-23\/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients. Arthritis Res Ther 18:52. https:\/\/doi.org\/10.1186\/s13075-016-0949-6","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"6070_CR34","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/rheumatology\/kem166","volume":"46","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Brandt J, Haibel H, Rudwaleit M, Sieper J et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 46(9):1450\u20131453. https:\/\/doi.org\/10.1093\/rheumatology\/kem166","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"6070_CR35","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Heijde D, Landewe R, Behier JM, Calin A, Olivieri I et al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52(6):1756\u20131765. https:\/\/doi.org\/10.1002\/art.21054","journal-title":"Arthritis Rheum"},{"issue":"10","key":"6070_CR36","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","volume":"71","author":"F Kroon","year":"2012","unstructured":"Kroon F, Landewe R, Dougados M, van der Heijde D (2012) Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 71(10):1623\u20131629. https:\/\/doi.org\/10.1136\/annrheumdis-2012-201370","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"6070_CR37","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D, Song IH, Hermann KG, Callhoff J et al (2016) Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 75(8):1438\u20131443. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207897","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6070_CR38","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.clim.2006.01.016","volume":"119","author":"JY Park","year":"2006","unstructured":"Park JY, Pillinger MH, Abramson SB (2006) Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin Immunol 119(3):229\u2013240. https:\/\/doi.org\/10.1016\/j.clim.2006.01.016","journal-title":"Clin Immunol"},{"issue":"6","key":"6070_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014591","volume":"7","author":"F Proft","year":"2017","unstructured":"Proft F, Muche B, Listing J, Rios-Rodriguez V, Sieper J, Poddubnyy D (2017) Study protocol: COmparison of the effect of treatment with Nonsteroidal anti-inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL) - an open-label randomized controlled multicenter trial. BMJ Open 7(6):e014591. https:\/\/doi.org\/10.1136\/bmjopen-2016-014591","journal-title":"BMJ Open"},{"issue":"5","key":"6070_CR40","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1172\/JCI28551","volume":"116","author":"V Krishnan","year":"2006","unstructured":"Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116(5):1202\u20131209. https:\/\/doi.org\/10.1172\/JCI28551","journal-title":"J Clin Invest"},{"key":"6070_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"Delgado-Calle J, Sato AY, Bellido T (2017) Role and mechanism of action of sclerostin in bone. Bone 96:29\u201337. https:\/\/doi.org\/10.1016\/j.bone.2016.10.007","journal-title":"Bone"},{"key":"6070_CR42","doi-asserted-by":"publisher","first-page":"9101964","DOI":"10.1155\/2018\/9101964","volume":"2018","author":"FM Perrotta","year":"2018","unstructured":"Perrotta FM, Ceccarelli F, Barbati C, Colasanti T, De Socio A, Scriffignano S et al (2018) Serum sclerostin as a possible biomarker in ankylosing spondylitis: a case-control study. J Immunol Res 2018:9101964. https:\/\/doi.org\/10.1155\/2018\/9101964","journal-title":"J Immunol Res"},{"key":"6070_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/nyas.12968","volume":"1364","author":"W Xie","year":"2016","unstructured":"Xie W, Zhou L, Li S, Hui T, Chen D (2016) Wnt\/beta-catenin signaling plays a key role in the development of spondyloarthritis. Ann N Y Acad Sci 1364:25\u201331. https:\/\/doi.org\/10.1111\/nyas.12968","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"6070_CR44","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13(2):156\u2013163. https:\/\/doi.org\/10.1038\/nm1538","journal-title":"Nat Med"},{"issue":"3","key":"6070_CR45","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/ard.2008.102046","volume":"69","author":"S Uderhardt","year":"2010","unstructured":"Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W et al (2010) Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69(3):592\u2013597. https:\/\/doi.org\/10.1136\/ard.2008.102046","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6070_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10067-019-04771-3","volume":"39","author":"K Gulyas","year":"2020","unstructured":"Gulyas K, Horvath A, Vegh E, Pusztai A, Szentpetery A, Petho Z et al (2020) Effects of 1-year anti-TNF-alpha therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 39(1):167\u2013175. https:\/\/doi.org\/10.1007\/s10067-019-04771-3","journal-title":"Clin Rheumatol"},{"issue":"1","key":"6070_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cytogfr.2012.06.003","volume":"24","author":"E Biver","year":"2013","unstructured":"Biver E, Hardouin P, Caverzasio J (2013) The \u201cbone morphogenic proteins\u201d pathways in bone and joint diseases: translational perspectives from physiopathology to therapeutic targets. Cytokine Growth Factor Rev 24(1):69\u201381. https:\/\/doi.org\/10.1016\/j.cytogfr.2012.06.003","journal-title":"Cytokine Growth Factor Rev"},{"issue":"22","key":"6070_CR48","doi-asserted-by":"publisher","first-page":"8793","DOI":"10.1073\/pnas.86.22.8793","volume":"86","author":"S Vukicevic","year":"1989","unstructured":"Vukicevic S, Luyten FP, Reddi AH (1989) Stimulation of the expression of osteogenic and chondrogenic phenotypes in vitro by osteogenin. Proc Natl Acad Sci U S A 86(22):8793\u20138797. https:\/\/doi.org\/10.1073\/pnas.86.22.8793","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"6070_CR49","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1083\/jcb.113.3.681","volume":"113","author":"A Yamaguchi","year":"1991","unstructured":"Yamaguchi A, Katagiri T, Ikeda T, Wozney JM, Rosen V, Wang EA et al (1991) Recombinant human bone morphogenetic protein-2 stimulates osteoblastic maturation and inhibits myogenic differentiation in vitro. J Cell Biol 113(3):681\u2013687. https:\/\/doi.org\/10.1083\/jcb.113.3.681","journal-title":"J Cell Biol"},{"issue":"3","key":"6070_CR50","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1002\/jbmr.5650090314","volume":"9","author":"SE Harris","year":"1994","unstructured":"Harris SE, Sabatini M, Harris MA, Feng JQ, Wozney J, Mundy GR (1994) Expression of bone morphogenetic protein messenger RNA in prolonged cultures of fetal rat calvarial cells. J Bone Miner Res 9(3):389\u2013394. https:\/\/doi.org\/10.1002\/jbmr.5650090314","journal-title":"J Bone Miner Res"},{"issue":"6","key":"6070_CR51","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1210\/endo.136.6.7750491","volume":"136","author":"FJ Hughes","year":"1995","unstructured":"Hughes FJ, Collyer J, Stanfield M, Goodman SA (1995) The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 136(6):2671\u20132677. https:\/\/doi.org\/10.1210\/endo.136.6.7750491","journal-title":"Endocrinology"},{"issue":"1","key":"6070_CR52","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/08977199308991582","volume":"9","author":"EA Wang","year":"1993","unstructured":"Wang EA, Israel DI, Kelly S, Luxenberg DP (1993) Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1\/2 and 3T3 cells. Growth Factors 9(1):57\u201371. https:\/\/doi.org\/10.3109\/08977199308991582","journal-title":"Growth Factors"},{"issue":"2","key":"6070_CR53","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1046\/j.1440-169x.1999.00421.x","volume":"41","author":"C Leclerc","year":"1999","unstructured":"Leclerc C, Duprat AM, Moreau M (1999) Noggin upregulates Fos expression by a calcium-mediated pathway in amphibian embryos. Dev Growth Differ 41(2):227\u2013238. https:\/\/doi.org\/10.1046\/j.1440-169x.1999.00421.x","journal-title":"Dev Growth Differ"},{"issue":"12","key":"6070_CR54","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1172\/JCI3459","volume":"102","author":"E Gazzerro","year":"1998","unstructured":"Gazzerro E, Gangji V, Canalis E (1998) Bone morphogenetic proteins induce the expression of noggin, which limits their activity in cultured rat osteoblasts. J Clin Invest 102(12):2106\u20132114. https:\/\/doi.org\/10.1172\/JCI3459","journal-title":"J Clin Invest"},{"issue":"2","key":"6070_CR55","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1002\/art.39433","volume":"68","author":"Z Xie","year":"2016","unstructured":"Xie Z, Wang P, Li Y, Deng W, Zhang X, Su H et al (2016) Imbalance between bone morphogenetic protein 2 and noggin induces abnormal osteogenic differentiation of mesenchymal stem cells in ankylosing spondylitis. Arthritis Rheumatol 68(2):430\u2013440. https:\/\/doi.org\/10.1002\/art.39433","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"6070_CR56","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1136\/annrheumdis-2013-203630","volume":"73","author":"FW Tsui","year":"2014","unstructured":"Tsui FW, Tsui HW, Las Heras F, Pritzker KP, Inman RD (2014) Serum levels of novel noggin and sclerostin-immune complexes are elevated in ankylosing spondylitis. Ann Rheum Dis 73(10):1873\u20131879. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203630","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6070_CR57","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landewe R, Einstein S, Ory P, Vosse D, Ni L et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324\u20131331. https:\/\/doi.org\/10.1002\/art.23471","journal-title":"Arthritis Rheum"},{"issue":"4","key":"6070_CR58","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN, Landewe R, Maksymowych WP, Kupper H et al (2009) Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 11(4):R127. https:\/\/doi.org\/10.1186\/ar2794","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"6070_CR59","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/acr.23097","volume":"69","author":"F Maas","year":"2017","unstructured":"Maas F, Arends S, Brouwer E, Essers I, van der Veer E, Efde M et al (2017) Reduction in spinal radiographic progression in ankylosing spondylitis patients receiving prolonged treatment with tumor necrosis factor inhibitors. Arthritis Care Res (Hoboken) 69(7):1011\u20131019. https:\/\/doi.org\/10.1002\/acr.23097","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"6070_CR60","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","volume":"77","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde D, Baraliakos X, Hermann KA, Landewe RBM, Machado PM, Maksymowych WP et al (2018) Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis 77(5):699\u2013705. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212377","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6070_CR61","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/ar2642","volume":"11","author":"RJ Lories","year":"2009","unstructured":"Lories RJ, Luyten FP, de Vlam K (2009) Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 11(2):221. https:\/\/doi.org\/10.1186\/ar2642","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"6070_CR62","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2106\/00004623-200401000-00013","volume":"86","author":"D Hannallah","year":"2004","unstructured":"Hannallah D, Peng H, Young B, Usas A, Gearhart B, Huard J (2004) Retroviral delivery of Noggin inhibits the formation of heterotopic ossification induced by BMP-4, demineralized bone matrix, and trauma in an animal model. J Bone Joint Surg Am 86(1):80\u201391. https:\/\/doi.org\/10.2106\/00004623-200401000-00013","journal-title":"J Bone Joint Surg Am"},{"issue":"3","key":"6070_CR63","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1359\/jbmr.2001.16.3.497","volume":"16","author":"P Aspenberg","year":"2001","unstructured":"Aspenberg P, Jeppsson C, Economides AN (2001) The bone morphogenetic proteins antagonist Noggin inhibits membranous ossification. J Bone Miner Res 16(3):497\u2013500. https:\/\/doi.org\/10.1359\/jbmr.2001.16.3.497","journal-title":"J Bone Miner Res"},{"issue":"11","key":"6070_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2017.e00450","volume":"3","author":"S Ghadakzadeh","year":"2017","unstructured":"Ghadakzadeh S, Hamdy RC, Tabrizian M (2017) Efficient in vitro delivery of Noggin siRNA enhances osteoblastogenesis. Heliyon 3(11):e00450. https:\/\/doi.org\/10.1016\/j.heliyon.2017.e00450","journal-title":"Heliyon"},{"issue":"1","key":"6070_CR65","doi-asserted-by":"publisher","first-page":"18000","DOI":"10.1038\/s41598-019-54549-5","volume":"9","author":"DH Lim","year":"2019","unstructured":"Lim DH, Lee EJ, Kwon OC, Hong S, Lee CK, Yoo B et al (2019) Effect of tumor necrosis factor inhibition on spinal inflammation and spinal ankylosis in SKG mice. Sci Rep 9(1):18000. https:\/\/doi.org\/10.1038\/s41598-019-54549-5","journal-title":"Sci Rep"},{"issue":"11","key":"6070_CR66","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","volume":"14","author":"EM Gravallese","year":"2018","unstructured":"Gravallese EM, Schett G (2018) Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 14(11):631\u2013640. https:\/\/doi.org\/10.1038\/s41584-018-0091-8","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"6070_CR67","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/jid.2012.194","volume":"133","author":"DA Martin","year":"2013","unstructured":"Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG et al (2013) The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 133(1):17\u201326. https:\/\/doi.org\/10.1038\/jid.2012.194","journal-title":"J Invest Dermatol"},{"issue":"3","key":"6070_CR68","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/1346-8138.14139","volume":"45","author":"E Ogawa","year":"2018","unstructured":"Ogawa E, Sato Y, Minagawa A, Okuyama R (2018) Pathogenesis of psoriasis and development of treatment. J Dermatol 45(3):264\u2013272. https:\/\/doi.org\/10.1111\/1346-8138.14139","journal-title":"J Dermatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06070-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06070-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06070-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,30]],"date-time":"2022-04-30T11:06:12Z","timestamp":1651316772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06070-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["6070"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06070-w","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]},"assertion":[{"value":"4 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}